Literature DB >> 25001387

BETs abet Tam-R in ER-positive breast cancer.

Prasanna G Alluri1, Irfan A Asangani2, Arul M Chinnaiyan3.   

Abstract

Epigenetic modifications such as histone acetylation play a central role in the transcriptional regulation of many oncogenic drivers. Accumulating evidence suggests that pharmacological modulation of certain key epigenetic reader proteins such as BRD2/3/4 may serve as an attractive strategy for treatment of many cancers, including tamoxifen-resistant breast cancer.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25001387      PMCID： PMC4123300          DOI： 10.1038/cr.2014.90

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  11 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Pathogenesis of NUT midline carcinoma.

Authors:  Christopher A French
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

Review 3.  A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.

Authors:  Nicholas Mitsiades
Journal:  Cancer Res       Date:  2013-07-25       Impact factor: 12.701

4.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

5.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

6.  Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer.

Authors:  Jian Shi; Yifan Wang; Lei Zeng; Yadi Wu; Jiong Deng; Qiang Zhang; Yiwei Lin; Junlin Li; Tiebang Kang; Min Tao; Elena Rusinova; Guangtao Zhang; Chi Wang; Haining Zhu; Jun Yao; Yi-Xin Zeng; B Mark Evers; Ming-Ming Zhou; Binhua P Zhou
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

7.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

8.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

9.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

10.  An epigenomic approach to therapy for tamoxifen-resistant breast cancer.

Authors:  Qin Feng; Zheng Zhang; Martin J Shea; Chad J Creighton; Cristian Coarfa; Susan G Hilsenbeck; Rainer Lanz; Bin He; Lei Wang; Xiaoyong Fu; Agostina Nardone; Yongcheng Song; James Bradner; Nicholas Mitsiades; Constantine S Mitsiades; C Kent Osborne; Rachel Schiff; Bert W O'Malley
Journal:  Cell Res       Date:  2014-05-30       Impact factor: 25.617
View more
  7 in total

Review 1.  The changing role of ER in endocrine resistance.

Authors:  Agostina Nardone; Carmine De Angelis; Meghana V Trivedi; C Kent Osborne; Rachel Schiff
Journal:  Breast       Date:  2015-08-10       Impact factor: 4.380

2.  Epigenetic therapies in heart failure.

Authors:  Michael Alexanian; Arun Padmanabhan; Timothy A McKinsey; Saptarsi M Haldar
Journal:  J Mol Cell Cardiol       Date:  2019-04-13       Impact factor: 5.000

3.  BEclear: Batch Effect Detection and Adjustment in DNA Methylation Data.

Authors:  Ruslan Akulenko; Markus Merl; Volkhard Helms
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

4.  The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

Authors:  Fang Xie; Mei Huang; Xiansheng Lin; Chenhai Liu; Zhen Liu; Futao Meng; Chao Wang; Qiang Huang
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

Review 5.  The emerging role of BET inhibitors in breast cancer.

Authors:  Angeliki Andrikopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios-Athanasios Dimopoulos; Flora Zagouri
Journal:  Breast       Date:  2020-08-13       Impact factor: 4.380

6.  TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers.

Authors:  A A Serandour; H Mohammed; A Miremadi; K W Mulder; J S Carroll
Journal:  Oncogene       Date:  2018-06-12       Impact factor: 9.867

7.  Acetylation of histone H3K27 signals the transcriptional elongation for estrogen receptor alpha.

Authors:  Yujing Gao; Lijia Chen; Yali Han; Fangrui Wu; Wen-Si Yang; Zheng Zhang; Tong Huo; Yingmin Zhu; Chengtai Yu; Hong Kim; Mark Lee; Zhen Tang; Kevin Phillips; Bin He; Sung Yun Jung; Yongcheng Song; Bokai Zhu; Rui-Ming Xu; Qin Feng
Journal:  Commun Biol       Date:  2020-04-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.